Academic Journal
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.
| العنوان: | Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. |
|---|---|
| المؤلفون: | Melief, Cornelis J M, Welters, Marij J P, Vergote, Ignace, Kroep, Judith R, Kenter, Gemma G, Ottevanger, Petronella B, Tjalma, Wiebren A A, Denys, Hannelore, van Poelgeest, Mariette I E, Nijman, Hans W, Reyners, Anna K L, Velu, Thierry, Goffin, Frédéric, Lalisang, Roy I, Loof, Nikki M, Boekestijn, Sanne, Krebber, Willem Jan, Hooftman, Leon, Visscher, Sonja, Blumenstein, Brent A, Stead, Richard B, Gerritsen, Winald, van der Burg, Sjoerd H |
| المصدر: | Science Translational Medicine, 12 (535) (2020-03-18) |
| بيانات النشر: | American Association for the Advancement of Science, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cancer Vaccines, Papillomavirus E7 Proteins, Papillomavirus Vaccines, Female, Human papillomavirus 16, Humans, Papillomavirus Infections, Uterine Cervical Neoplasms, Medicine (all), General Medicine, Human health sciences, Immunology & infectious disease, Sciences de la santé humaine, Immunologie & maladie infectieuse |
| الوصف: | Therapeutic cancer vaccines have effectively induced durable regressions of premalignant oncogenic human papilloma virus type 16 (HPV16)-induced anogenital lesions. However, the treatment of HPV16-induced cancers requires appropriate countermeasures to overcome cancer-induced immune suppression. We previously showed that standard-of-care carboplatin/paclitaxel chemotherapy can reduce abnormally high numbers of immunosuppressive myeloid cells in patients, allowing the development of much stronger therapeutic HPV16 vaccine (ISA101)-induced tumor immunity. We now show the clinical effects of ISA101 vaccination during chemotherapy in 77 patients with advanced, recurrent, or metastatic cervical cancer in a dose assessment study of ISA101. Tumor regressions were observed in 43% of 72 evaluable patients. The depletion of myeloid suppressive cells by carboplatin/paclitaxel was associated with detection of low frequency of spontaneous HPV16-specific immunity in 21 of 62 tested patients. Patients mounted type 1 T cell responses to the vaccine across all doses. The group of patients with higher than median vaccine-induced immune responses lived longer, with a flat tail on the survival curve. This demonstrates that chemoimmunotherapy can be exploited to the benefit of patients with advanced cancer based on a defined mode of action. |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501 article peer reviewed |
| اللغة: | English |
| Relation: | https://syndication.highwire.org/content/doi/10.1126/scitranslmed.aaz8235; urn:issn:1946-6234; urn:issn:1946-6242 |
| DOI: | 10.1126/scitranslmed.aaz8235 |
| URL الوصول: | https://orbi.uliege.be/handle/2268/309154 |
| Rights: | open access http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsorb.309154 |
| قاعدة البيانات: | ORBi |
| DOI: | 10.1126/scitranslmed.aaz8235 |
|---|